Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: A study from the acute leukemia working party of the european society for blood and marrow transplantation

D Salvatore, M Labopin, Annalisa Ruggeri, G Battipaglia, A Ghavamzadeh, F Ciceri, D Blaise, W Arcese, G Sociè, JH Bourhis, MT Van Lint, Benedetto Bruno, A Huynh, Stella Santarone, E Deconinck, M Mohty, A Nagler

Research output: Contribution to journalArticle

Abstract

Allogeneic hematopoietic stem cell transplantation is the optimal care for patients with high-risk or intermediate -acute myeloid leukemia. In patients lacking matched sibling donor, haploidentical donors are an option. We compared outcomes of unmanipulated (Haplo) to matched sibling donor transplant in acute myeloid leukemia patients in first complete remission. Included were intermediate and high-risk acute myeloid leukemia in first complete remission undergoing Haplo and matched sibling donor transplant from 2007-2015, and reported to the ALWP of the EBMT. A propensity score technique was used to confirm results of main analysis: 2 matched sibling donors were matched with 1 Haplo. We identified 2654 pts (Haplo =185; matched sibling donor =2469), 2010 with intermediate acute myeloid leukemia (Haplo=122; matched sibling donor =1888) and 644 with high-risk acute myeloid leukemia (Haplo =63; matched sibling donor =581). Median follow up was 30 (range 1-116) months. In multivariate analysis, in intermediate -acute myeloid leukemia patients, Haplo resulted in lower leukemia-free survival (Hazard Ratio 1.74; P
Original languageEnglish
Pages (from-to)1317-1328
Number of pages12
JournalHaematologica
Volume103
Issue number8
DOIs
Publication statusPublished - 2018

Fingerprint Dive into the research topics of 'Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: A study from the acute leukemia working party of the european society for blood and marrow transplantation'. Together they form a unique fingerprint.

  • Cite this